Company intelligence / Profile preview

Duracar

San Diego, California, United Statesduracar.eu ↗

Ownership: Private
Development stage: Other

Overview

DuraCAR is an experimental chimeric antigen receptor T-cell (CAR-T) therapeutic platform being developed by Regen BioPharma. It targets CD19 and incorporates siRNA-mediated modulation of NR2F6 to potentially enhance immunosuppressive properties or tumor-killing activity. Preclinical studies have shown that these engineered T cells can elevate NR2F6 expression, which may suppress autoimmunity or improve anti-tumor effects. The program remains in preclinical development with ongoing validation experiments through contract research organizations.

Therapeutic areas: ImmunologyOncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Partnerships

Contract Research Organizations for preclinical work

Beyond the preview

Go deeper on Duracar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Duracar.

Explore the full profile